Clariane SEFRA:KO2 +1.62%61 EBITDA Margin % is 26.37% as of Dec. 2025, which is 30% above its 10-year median of 20.27. GuruFocus rates FRA:KO2 with a GF Score™ of 61/100 and a GF Value™ of €2.46 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Clariane SE ranks better than 79.64% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Clariane SE's EBITDA for the
six
months ended in Dec. 2025 was €700 Mil. Clariane SE's Revenue for the
six
months ended in Dec. 2025 was €2,655 Mil. Therefore, Clariane SE's EBITDA margin for the quarter that ended in Dec. 2025 was 26.37%.
Clariane SE (FRA:KO2) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Clariane SE EBITDA Margin % Related Terms
Clariane SE EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Clariane SE's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:KO2 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Clariane SE's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clariane SE EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Clariane SE's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clariane SE (FRA:KO2) has a EBITDA Margin % of 26.37% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Clariane SE and its competitors. This is 30% above median its historical median of 20.27. Over the past decade, Clariane SE's EBITDA Margin % has ranged from 12.30 to 23.54. According to the industry distribution chart, Clariane SE ranks #136 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 20.4%.
Is Clariane SE's EBITDA Margin % too high?
Clariane SE's current EBITDA Margin % of 26.37% is 30% above median its 10-year median of 20.27. Over the past 10 years, this metric has ranged from a low of 12.30 to a high of 23.54. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Clariane SE's value of 26.37% is 158.3% above this industry median. Based on the distribution chart, Clariane SE ranks #136 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Clariane SE has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Clariane SE ranks #136 out of 668 companies for EBITDA Margin %. This places Clariane SE in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Clariane SE's value of 26.37% is 158.3% above this benchmark. Historically, Clariane SE's own EBITDA Margin % has ranged from 12.30 to 23.54 over the past decade. While the company's 10-year median is 20.27 vs. the industry median of 10.21, Clariane SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clariane SE's current EBITDA Margin % of 26.37% is 158.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Clariane SE and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clariane SE's current EBITDA Margin % is 26.37%, which is 30% above median its own 10-year median of 20.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (FRA:KO2) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.46, compared to a current price of €4.14 — trading 68.3% above its estimated fair value. The current EBITDA Margin % is 26.37%, which is 30% above median its 10-year median of 20.27 and 158.3% above the Healthcare Providers & Services industry median of 10.21. Clariane SE's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Clariane SE (FRA:KO2), the current EBITDA Margin % is 26.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clariane SE (FRA:KO2) Overvalued in 2026?
Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued.
The current stock price of €4.14 is trading 68.3% above its estimated GF Value™ of €2.46.
GuruFocus considers Clariane SE to be Significantly Overvalued.
Key valuation signals for FRA:KO2:
EBITDA Margin %: 26.37% (30% above median its 10-year median of 20.27)
GF Value™: €2.46 vs. price of €4.14 (68.3% above fair value)
Industry Position: 158.3% above the Healthcare Providers & Services median (#136 of 668)
No single metric tells the full story. See the FRA:KO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
61GF Score
Get the complete analysis for FRA:KO2
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KO2 has been successfully added to your 
